Baseline β-CTX and BMI predict suitability for deferred zoledronic acid redosing beyond 12 months in postmenopausal Indian women with osteoporosis
Bone · 2026
DOI: 10.1016/j.bone.2026.118003 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Bone, 2026. Verfasst von Vivek Jha und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India. Hauptthemen laut MEDLINE: Collagen Type I, Imidazoles, Diphosphonates, Body Mass Index. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To evaluate whether baseline bone turnover markers (BTMs), particularly plasma β-C-terminal telopeptide of type I collagen (β-CTX), and body mass index (BMI) predict the feasibility and short-term safety of deferring zoledronic acid redosing beyond 12 months in postmenopausal Indian women with osteoporosis. METHODS: In this prospective observational study, 50 treatment-naïve postmenopausal women with DXA-confirmed osteoporosis received intravenous zoledronic acid (5 mg). At the 12-month visit, β-CTX guided repeat dosing: women with β-CTX ≥300 pg/mL were redosed, whereas those with β-CTX 12 months). RESULTS: Twenty-five women underwent delayed redosing (median interval 18.5 months). Compared with standard dosing, the delayed group had lower baseline β-CTX (582 vs 866 pg/mL; p < 0.001) and lower BMI (23.4 ± 5.5 vs 25.7 ± 2.0 kg/m2; p = 0.008). On multivariable analysis, lower baseline β-CTX (adjusted OR per 100 pg/mL 0.48; 95% CI 0.31-0.73; p = 0.001) and lower BMI (adjusted OR per kg/m2 0.81; 95% CI 0.67-0.98; p = 0.031) independently predicted delayed redosing. BMD gains were comparable between groups and no new vertebral fractures occurred during 2-year follow-up. CONCLUSION: Lower baseline bone turnover and lower BMI were associated with delayed zoledronic acid redosing, supporting a biomarker-guided approach to individualized treatment intervals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India.
- Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India. Electronic address: bhadadask@rediffmail.com.
Zitieren
APA
Jha, V., Bhadada, S. K., Mukherjee, S., Pal, R., & Kharbanda, C. (2026). Baseline β-CTX and BMI predict suitability for deferred zoledronic acid redosing beyond 12 months in postmenopausal Indian women with osteoporosis. Bone. https://doi.org/10.1016/j.bone.2026.118003
Vancouver
Jha V, Bhadada SK, Mukherjee S, Pal R, Kharbanda C. Baseline β-CTX and BMI predict suitability for deferred zoledronic acid redosing beyond 12 months in postmenopausal Indian women with osteoporosis. Bone. 2026. doi:10.1016/j.bone.2026.118003
BibTeX
@article{Jha2026,
author = {Jha, Vivek and Bhadada, Sanjay Kumar and Mukherjee, Soham and Pal, Rimesh and Kharbanda, Chirag},
title = {Baseline β-CTX and BMI predict suitability for deferred zoledronic acid redosing beyond 12 months in postmenopausal Indian women with osteoporosis},
journal = {Bone},
year = {2026},
doi = {10.1016/j.bone.2026.118003}
}
EUVIMED